IL17A and metabolic syndrome: We also observed increased levels of IL17 in patients with metabolic manifestations (3.0 ± 0.5 vs. 1.4 ± 0.3 pg/mL; p = 0.022) (Fig. 3e), and of CX3CL1 in patients with dyslipidaemia (1.2 ± 0.2 vs. 0.8 ± 0.1; p = 0.009), hypertension (1.2 ± 0.1 vs. 0.8 ± 0.1; p = 0.028) or metabolic syndrome (1.3 ± 0.2 vs. 0.9 ± 0.1; p = 0.020).